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Object. Cerebral vasospasm after subarachnoid hemorrhage (SAH) continues to be a major source of morbidity in 
patients despite significant clinical and basic science research. Efforts to prevent vasospasm by removing spasmogens 
from the subarachnoid spacc have produced mixed results. The authors hypothesize that lumbar cisternal drainage can 
remove blood from the basal subarachnoid spaces more effectively than an external ventricular drain (EVD). This non­
randomized, controlled-cohort study was undertaken to evaluate the effectiveness of a lumbar drain in patients with 
SAH compared with those in whom an EVD or no form of cerebrospinal fluid (CSF) drainage was used to prevent the 
development of clinical vasospasm and its sequelae.
Methods. The authors collected data on 266 patients with nontraumatic SAH who were admitted to the University 
of Utah Health Sciences Center between January 1994 and January 2003. Of these, 167 met the study entry criteria. 
The treatment group consisted of 81 patients in whom a lumbar drain had been placed for CSF shunting, whereas the 
control group was composed of 86 patients who received no form of CSF drainage or who were treated solely with an 
EVD. Primary outcome measures were as follows: 1) clinically evident vasospasm; 2) the need for endovascular inter­
vention; 3) vasospasm-induced infarction; 4) disposition at time of discharge; and 5) Glasgow Outcome Scale (GOS) 
score at 1 to 3 months postdischarge. Secondary outcomes included length of stay and the need for CSF shunting.
The presence of a lumbar drain conferred a statistically significant protective and beneficial effect across all out­
come measures, reducing the incidence of clinical vasospasm from 51 to 17%, the need for angioplasty from 45 to 
17%, and the occurrence of vasospastic infarction from 27 to 7% (all p ^  0.001-0.008). Patients in the treatment group 
were more likely to be discharged home (54% compared with 25%, p = 0.002) and to have a GOS score of 5 at fol­
low up (71% compared with 35%, p <  0.001). The mean number of days spent in the intensive care unit and in the 
hospital overall was also fewer in the treatment group. A similar degree of benefit was found in patients with different 
Fisher grades and regardless of whether an EVD was needed on presentation, both by subgroup analysis and multi­
variate logistic regression modeling. There was no statistical difference between the groups in terms of patients requir­
ing a shunt. Complications with lumbar drains were rare and yielded no permanent sequelae.
Conclusions. Shunting of CSF through a lumbar drain after an SAH markedly reduces the risk of clinically evident 
vasospasm and its sequelae, shortens hospital stay, and improves outcome. Its beneficial effects arc probably mediat­
ed through the removal of spasmogens that exist in the CSF. The results of this study warrant a randomized clinical 
trial, which is currently under way.
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^  ~r asospasm  continues to be a major cause of morbid- 
\ /  ity after aneurysmal SAH. Although much has been 
V elucidated regarding its pathophysiology, it remains 
an incompletely solved problem. As improved emergency 
medical services, diagnostic testing, and rapid treatment 
have decreased the mortality rate from aneurysmal SAH, 
there has been a concomitant increase in the relative con­
tribution of vasospasm to the overall outcome. A number 
of significant achievements have improved our ability to 
manage vasospasm, but have not eliminated it as a clinical 
entity.
Abbreviations used in this paper: Cl = confidence interval; CSF = 
cerebrospinal fluid; CT = computerized tomography; EVD = exter­
nal ventricular drain; GOS = Glasgow Outcome Scale; ICP = intra­
cranial pressure; ICU = intensive care unit; MCA = middle cerebral 
artery; OR = odds ratio; rt-PA = recombinant tissue plasminogen 
activator; SAH = subarachnoid hemorrhage; TCD = transcranial 
Doppler.
Foremost among these improvements was the introduc­
tion of triple-H therapy in the early 1980s.530'51 Nimodipine, 
which was introduced for widespread clinical use in 1985, 
reduced the overall percentage of patients with severe va­
sospasm from 30 to 20%, but it did not seem to decrease 
the incidence of vasospasm identified on angiography.2'6'1-*- 
49,52,5.? jn iate 1980s, endovascular techniques such as an­
gioplasty and administration of intraarterial chemical vaso­
dilators such as papaverine enabled the neurological rescue 
of many patients, thereby further improving their overall 
outcomk3'9'11'12'14'17'42'*'47'55'56'61' Despite all these advances, va­
sospasm still contributes to poor outcome in approximately
10 to 40% of patients with dense SAH .8-1531 There is still no 
effective means to prevent vasospasm, and clinical practice 
now involves the intensive management of its effects while 
the disease runs its course. Management of vasospasm cur­
rently accounts for a substantial proportion of the duration 
and cost of the hospital stay.
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Research has clearly shown that the pathophysiology of 
vasospasm is directly related to the presence of blood in the 
subarachnoid space surrounding the cerebral conductance 
vessels.3*76 Fisher, et al.,is first noted this relationship in 
1980, and their grading scheme remains the mostly wide­
ly applied means of predicting vasospasm risk.19 Because 
hemolysis of blood is the primary inciting agent for vaso­
spasm, it would follow that strategies to facilitate the clear­
ance of blood from the subarachnoid spaces would decrease 
cerebral vasospasm. This strategy has been studied by a 
number of investigators.16-’ 53’ 35,7-4,-44-4S-5a64/;,5J0 7::j4J7 Cister­
nal administration of thrombolytic/fibrinolytic therapy was 
first introduced in 1991 and has been thoroughly evaluated, 
including a well-conducted randomized controlled trial.3236 
43,44,6?-*5,70,71,74,77 a  number of Japanese groups have advo­
cated cisternal irrigation therapy with inflow and outflow 
catheters placed in the cranial subarachnoid spaces.3537-48-7’ 
This is usually coupled with other modalities such as daily 
“head-shaking” and fibrinolytic therapy. These therapies 
have not gained widespread acceptance because of mixed 
results, the potential for morbidity from placing drains with­
in the cisternal spaces, and the fear of hemorrhagic compli­
cations.66'73
We hypothesized that lumbar CSF drainage may repre­
sent a simple and effective way to increase the clearance 
of blood from the subarachnoid spaces and consequently 
decrease the incidence of clinically significant vasospasm. 
Draining CSF from the lumbar cistern would be expected to 
promote circulation of clear, newly formed CSF from the 
cerebral ventricles through the subarachnoid spaces, espe­
cially if the arachnoidal membranes and/or lamina termi- 
nalis were opened at the time of surgery. Moreover, lumbar 
drainage would also promote removal of the red cell mass 
from the intrathecal space, which represents the largest of 
all subarachnoid cisterns. Conversely, CSF drainage direct­
ly from the lateral ventricles may contribute to stasis of 
hemorrhage within the subarachnoid cisterns, so that ven­
tricular drainage in those patients may actually add to the 
risk that cerebral vasospasm will develop. We have been 
using lumbar CSF drainage after SAH for the last 9 years, 
and now report how this affects the incidence of vasospasm 
in comparison to a group of patients whose SAH was man­
aged with conventional or no CSF drainage.
Clinical M aterial and M ethods
This study was made possible by differences in practice 
preference between two groups of cerebrovascular sur­
geons at the University of Utah over a 9-year period. One 
group used EVDs for CSF drainage in the postoperative 
period, if they believed it was necessary. The other group 
preferentially used lumbar CSF drainage in patients with 
high-grade SAHs according to the Fisher scale when this 
procedure was not contraindicated by safety concerns. 
Nearly equal numbers of patients with SAH were treated 
with one of these two management strategies. All other as­
pects of care, as described later, were similar.
Patient Population
Patients who suffered nontraumatic SAH between Jan­
uary 1994 and January 2003 were identified from a clinical
database maintained in the Department of Neurosurgery at 
the University of Utah. Clinical records from admission up 
to the time of discharge were available and were reviewed. 
The University of Utah's institutional review board autho­
rized all data collection and analysis.
Patient Demographics and Data
Between January 1994 and January 2003, 266 patients 
with nontraumatic SAH were treated at the University of 
Utah Health Sciences Center. From this population, 99 
patients were excluded from this study for various reasons. 
Forty-four patients had only Fisher Grade 1 or 2 hemor­
rhages; clinically evident vasospasm developed in only one, 
for an overall incidence of 2.3%. We excluded 27 patients 
who presented in poor neurological condition and either 
never significantly improved or died early. An additional 12 
patients who were in poor neurological condition after an­
eurysm treatment were excluded. Finally, 16 patients who 
presented for treatment 4 or more days after their index 
hemorrhage were also disqualified. This left 167 patients 
with high-grade hemorrhages (Fisher Grades 3, 3+4, and 4) 
who were in satisfactory neurological condition before the 
onset of vasospasm as the core patient population for this 
study.
Patient Selection and Clinical Management
All patients were assigned a Hunt and Hess grade’ 4 at the 
time of admission according to neurological parameters 
only. The presence of serious systemic disease was not used 
to upgrade the Hunt and Hess score. On arrival, all patients 
were systemically and neurologically resuscitated and sta­
bilized, if necessary, with intubation, mannitol, and mod­
erate hyperventilation therapy. An EVD was placed im­
mediately if neuroimaging or clinical features indicative 
of elevated ICP or symptomatic acute hydrocephalus were 
present. Patients were also classified according to the den­
sity of their SAH on the initial CT scan by using a modified 
Fisher grading system. This modification creates a new 
Grade 3+4 category for patients with both dense subarach­
noid blood and intraparenchymal/intraventricular hemor­
rhages of 5 ml or more (diameter >  2 cm). Examples of CT 
scans obtained in a patient assigned to this Fisher 3+4 cate­
gory are displayed in Fig. 1.
We excluded from analysis all patients whose neurologi­
cal condition was too poor to allow clinical recognition of 
the signs and symptoms of cerebral vasospasm. This in­
cluded all patients in Hunt and Hess Grade V who failed to 
improve substantially with either initial resuscitation or 
surgical intervention, those who died before clinical vaso­
spasm developed, patients who sustained a severe neuro­
logical deficit from aneurysm treatment (coma with Glas­
gow Coma Scale motor score <  4), and those in whom 
there was a delay of 4 or more days in presenting to our 
institution after their index SAH. We did not exclude pa­
tients who may have sustained a minor sentinel hemorrhage 
more than 4 days before admission.
With the exception of CSF drainage, all patients received 
treatment according to a consistent protocol. This included 
early surgical occlusion of the ruptured aneurysm with clip 
or coil placement (<  36 hours after admission); prophylac­
tic hypervolemic therapy with central venous catheters or 
Swan-Ganz catheters; administration of nimodipine; daily
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Fig. 1. Upper: Noncontrast axial CT scans demonstrating a 
Fisher Grade 3+4 SAH. There is dense blood within the basal cis­
terns (left) as well as significant intraventricular hemorrhage and 
a perisylvian intraparenchymal hemorrhage (right) Lower: Bar 
graph showing the risk of suffering clinical vasospasm based on our 
modified Fisher grading scheme. Patients with Fisher Grade 3+4 are 
at greatest risk (59%).
TCD ultrasonography examinations; and rigorous monitor­
ing and correction of electrolyte, blood gas, and serum anti­
convulsant drag levels and hydrocephalus. In patients who 
were treated surgically, the accessible basal cisterns were 
opened and cleaned of blood by suction and irrigation. All 
patients underwent cerebral angiography if vasospasm was 
suspected based on clinical evidence. At the onset of a neu­
rological change indicative of vasospasm, patients were 
given a bolus of crystalloid or colloid and their total fluid 
intake was titrated to a higher central venous pressure, or 
to the point of maximum cardiac output on the Starling 
curve if a Swan-Ganz catheter was used. Vasopressor med­
ications were administered to elevate blood pressure if clin­
ical improvement was not achieved or sustained with hy­
pervolemia. At the discretion of the attending surgeon, in 
consultation with the interventional radiologist, severe or 
refractory vasospasm was treated with either balloon an­
gioplasty or repeated intraarterial infusion of papaverine. 
In three patients (all in the lumbar drainage group), moder­
ate to severe vasospasm was detected on surveillance TCD 
studies and angiography in the absence of clinically ap­
parent neurological change, and prophylactic endovascular 
therapy was initiated. For the purpose of data analysis, these 
patients were scored as having vasospasm. Otherwise, pro­
phylactic angioplasty was not routinely used.
Definition o f Vasospasm and Vasospasm-Related Infarction
Vasospasm was diagnosed using the criteria defined in 
the tirilizad trials:21- —938 1 ) onset of new neurological de­
ficits such as confusion, disorientation, drowsiness, or focal 
motor deficit during posthemorrhage Days 4 to 14; 2) neg­
ative findings on CT scans obtained to rule out other caus­
es of neurological deterioration such as hemorrhage, cere­
bral edema, or hydrocephalus; 3) no other identifiable cause 
of neurological deterioration such as hyponatremia (<  132 
mEq/L), hypoxia, drug toxicity, infection, or seizures; and 
4) evidence of vasospasm on serial TCD ultrasonography 
examinations or a cerebral angiogram demonstrating vas­
cular narrowing affecting a territory concordant with the 
suspected source of the change in findings on neurological 
examination. Cerebral infarction caused by vasospasm was 
diagnosed if either a delayed ischemic deficit became sus­
tained beyond the risk period of cerebral vasospasm (indi­
cated by normal results on TCD examination or angiog­
raphy) or if imaging studies revealed a region of cerebral 
infarction in a vascular distribution consistent with the pa­
tient's vasospasm.
Cerebrospinal Fluid Drainage Methods
Any patient who presented with intracranial hyperten­
sion, which was usually caused by acute symptomatic hy­
drocephalus, was treated with an EVD in a conventional 
fashion. Lumbar CSF drainage in these patients was initiat­
ed only when it was deemed safe, as evidenced by the pres­
ence of an unobstructed ventricular system and the absence 
of mass lesions (hemorrhage or cerebral edema) causing 
midline shift. Lumbar drains were typically placed in pa­
tients at the time of surgery and were kept closed until post­
operative Day 1. At the surgeon's discretion, CSF was di­
verted using the lumbar drain intraoperatively to facilitate 
brain relaxation. If the postoperative CT scan demonstrated 
no contraindication, the lumbar drain was opened. In those 
patients who initially received EVDs for acute or obstruc­
tive hydrocephalus, we would transition the CSF drain­
age from the ventricular to the lumbar route as the patient's 
clinical condition and neuroimaging studies allowed, often 
overlapping the use of both drains for several days.
Lumbar CSF drainage was continued throughout the va­
sospasm risk period (drain height 5-10 cm above the exter­
nal auditory canal); the collection rate was targeted at 5 to
10 ml/hour. Lumbar drainage was stopped once the CSF 
was no longer visibly hemorrhagic and the risk period for 
vasospasm had passed. For the purposes of data analysis, 
we considered only patients in whom lumbar CSF drainage 
was started by posthemorrhage Day 4 and continued for a 
minimum of 3 days to have undergone an effective trial of 
lumbar drainage.
Outcome Measures
There were five primary outcome measures in this study: 
1 ) clinically evident vasospasm; 2 ) use of cerebral angio­
plasty and/or intraarterial papaverine infusion; 3) vaso­
spasm-related cerebral infarction; 4) disposition of the pa­
tient at the time of discharge; and 5) GOS26 score at 1- to 
3-month follow up. Secondary outcome measures included 
duration of stay in the ICU, overall acute hospital duration 
of stay (excluding inpatient rehabilitation), and the need for 
permanent CSF diversion (shunt placement).
Calculations and Statistical Analysis
Tests of associations between the primary outcome mea-
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TABLE 1
Characteristics o f the lumbar drain and control 




no. of patients 





Hunt & Hess grade (%) 
I 7 (9) 5 (6)
NS
II 30(37) 25 (29)
in 25 (31) 22 (26)
IV 15 (18) 28 (32)
V 4 (5) 6 ( 7)
Fisher grade (%) 
3 64 (79) 47(55)
0.001
3+4 17(21) 34(39)
4 0 (0) 5 (6)
EVD on admission (%) 27(33) 43 (50) 0.024
source of bleeding (%) 
ACoA 18 22) 30(35)
NS
PCoA 15 19) 11 (13)
MCA bif 11 14) 12(14)
posterior circt 11 14) 14(16)
nonaneurysmal 12 15) 7(8)
othert 17 21) 12(14)
intraop rupture (%) 6 7) 11 (13) NS
coil insertion (%) 3 4) 3 (3) NS
* ACoA = anterior communicating artery: bif = bifurcation; circ = circu­
lation; LD = lumbar drain; NS = nonsignificant; PCoA = posterior commu­
nicating artery.
t  Includes basilar, vertebral, posterior inferior cerebellar, and posterior 
cerebral arteries.
£ Includes patients with multiple aneurysms in whom the source of the 
hemorrhage could not be reliably determined ( internal carotid artery bifur­
cation aneurysms, distal anterior cerebral artery aneurysms, and so on).
sures and the method of CSF drainage were performed 
using chi-square analysis. Statistical significance was set 
at probability values of less than 0.05. Subgroup-specific 
analysis was also performed. Potential confounding fac­
tors were investigated using multivariate logistic regres­
sion. The ORs and their 95% CIs obtained from the logistic 
regression models are reported. All statistical analysis was 
performed using commercially available software (Stata 
Corp., College Station, TX).
R esu lts
The creation of a Fisher Grade 3+4 category (51 patients) 
proved useful because these individuals had the highest 
overall risk of vasospasm. Figure 1 upper illustrates a typ­
ical example of a Fisher Grade 3+4 hemorrhage, and Fig.
1 lower illustrates, based on our data, the risk of clinical­
ly evident vasospasm as a function of this modified Fisher 
scale. Among our patients in Fisher Grade 1 or 2, symptom­
atic vasospasm developed in only one patient, and that pa­
tient is believed to have suffered a sentinel hemorrhage 4 
days before admission. Regardless of treatment group, 24% 
of Fisher Grade 3 patients and 59% of Fisher Grade 3+4 pa­
tients experienced clinically significant vasospasm. Patients 
who were assigned a Fisher grade of 4 were relatively few 
(five patients). Of these individuals vasospasm developed 
in two, both of whom harbored MCA aneurysms with large 
perisylvian intraparenchymal hemorrhages and suffered va-
Fig. 2. Photograph showing CSF collected in one patient with a 
Fisher Grade 3 SAH in whom both an EVD and a lumbar drain 
were placed. Our hypothesis for this study is exemplified in this pic­
ture: the CSF from the lumbar drain is markedly bloody compared 
with the CSF obtained from the EVD.
sospasm in the MCA distribution. We believe that their va­
sospasm occurred as a result of the surgical evacuation of 
the hematoma through the sylvian fissure, which placed it 
in communication with the adjacent subarachnoid space.
The methods used for CSF drainage were as follows: an 
EVD was used in 68 patients (40.7%) and no form of 
drainage was used in 18 ( 10 .8%); these groups constitut­
ed our control cohort of 86 patients. Fifty-eight patients 
(34.7%) received postoperative lumbar drains and another
23 (13.8%) required EVDs initially but were converted to 
lumbar drains postoperatively, within 4 days of their hem­
orrhage. These last two groups composed our lumbar drain 
cohort of 81 patients. The characteristics of the two cohorts 
are shown in Table 1. Using chi-square tests, differences in 
the composition of the two groups were evaluated. There 
were no differences in patient age. Hunt and Hess grade, 
source of hemorrhage, intraoperative rupture, or use of en­
dovascular coils. Nevertheless, there were statistical dif­
ferences between the two groups in the Fisher grade (p = 
0.001), and whether an EVD was placed on admission (p = 
0.024). The control group included more Fisher Grade 3+4 
patients (39% compared with 21%) and had more patients 
who required an EVD on admission (51 % compared with 
33%) compared with the lumbar drain group. All of the 
nonaneurysmal hemorrhages (19 lesions) included in this 
study represented patients with densely packed, pan-cister­
nal hematomas, not the classic perimesencephalic hemor­
rhage in a patient at low risk for vasospasm. Surgery was 
performed in 80% of patients in the lumbar drain group 
compared with 88% in the control group, and only three pa­
tients in each group were treated with coil placement.
Primary and Secondary Outcomes
As illustrated in Fig. 2, the effect of lumbar CSF drain­
age on mobilization of blood from the subarachnoid space 
was dramatic. Typically, CSF from the lumbar cistern was 
densely hemorrhagic for the initial days of CSF drainage 
and then progressively cleared. By contrast, CSF drained
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TABLE 2
Primary and secondary outcomes in 167 patients 
with SAH who underwent CSF drainage
Outcome
Group
LD Control p Value
no. of patients 81 86
primary measure
clinical vasospasm (%) 14(17) 44(51) <0.001
angioplasty/papaverine (%) 14(17) 39 (45) 0.001
vasospasm-related 
infarction (%) 6 (7) 23 (27) 0.008
disposition (%) 
home 44 (54) 22 (25)
0.002
inpatient rehabilitation 26(32) 41 (48)
extended care facility 9(11) 19(22)
death 2 (3) 4 (5)
GOS score (%)* 
1 2 (3) 4 (5)
<0.001
2 0 4 (5)
3 13 (16) 31 (40)
4 8(10) 12(15)
5 56(71) 27 (35)
secondary measure 
LOS (mean no. of days) 
ICU 13 16 0.0077
hospital 17 21 0.0014
shunt (%) 19 (24) 28 (36) 0.145
* Scores w'ere assigned at 1- to 3-month follow-up review's. The GOS
score could not be accurately assessed for two patients in the LD group and 
eight in the control group. Abbreviation: LOS = length of stay.
from the ventricle was often considerably less hemorrhag­
ic, indicating limited circulation within the subarachnoid 
space before withdrawal.
Table 2 shows the effects of using lumbar CSF drainage 
on our various primary outcome measures. For the entire 
cohort of patients, lumbar CSF drainage significantly re­
duced the incidence of clinical vasospasm from 51 to 17%, 
the need for endovascular vasospasm treatment from 45 
to 17%, and the risk of cerebral infarction from 27 to 7%. 
Those patients who did not receive a lumbar drain had a 
2.9-, 2.6-, and 3.7-fold greater risk of experiencing clinical 
vasospasm, requiring endovascular procedures, and suf­
fering a stroke, respectively, than those in whom a lumbar 
drain was placed. Another means of assessing the effective­
ness of a lumbar drain is to calculate the number of patients 
who needed to be treated to prevent adverse outcomes. The 
number of patients who need to be treated with a lumbar 
drain to prevent one case of vasospasm and one of stroke 
are three and five, respectively. Four patients need to be 
treated with a lumbar drain before one patient is spared an 
endovascular procedure for vasospasm.
Lumbar CSF drainage also had a positive influence on 
patient disposition and functional outcome. As seen in 
Table 2, the proportion of patients in the lumbar drain group 
who were discharged directly home was more than twice 
that of the control group, with corresponding decreases in 
death, discharge to convalescent facilities, and inpatient 
rehabilitation. Similarly, twice as many patients in the lum­
bar drain group had a 1- to 3-month GOS score of 5 com­
pared with the control group. Patients in the control group 
spent a mean of 16 days in the ICU, compared with 13 days 
for the lumbar drain group (t-test, p = 0.0077). Likewise, 
the mean hospital stay for the control group was longer than
TABLE 3




clinical vasospasm 0.20 (0.10-0.41) 0.20 (0.09-0.44)
angioplasty/papaverine 0.25 (0.12-0.52) 0.27 (0.12-0.60)
vasospasm-related infarction 0.21 (0.08-0.57) 0.17 (0.08-0.64)
* The table show's the crude and the adjusted ORs for different outcome 
measures when the lumbar drain group was compared with the control 
group. The crude OR was calculated from 2 X 2  tables, whereas the adjust­
ed OR w'as derived from the logistic regression model. The results w'ere 
controlled for patient age, Fisher grade. Hunt and Hess grade, intraopera­
tive rupture, need for EVD on admission, and aneurysm location.
that of the lumbar drain group (21 compared with 17 days, 
t-test, p = 0.0014). Of the possible 162 patients, excluding 
the five who died before we could determine whether they 
needed a shunt, 24% in the lumbar drain group and 34% in 
the control group required a shunt. This difference did not 
reach statistical significance, however (p = 0.145).
Logistic Regression Analysis
Because there were imbalances in Fisher grade (3 com­
pared with 3+4) and in the need for EVD on admission (Ta­
ble 1 ), we analyzed for these effects in two different ways. 
First, we performed a logistic regression analysis to identi­
fy factors that predicted the three main binaiy outcomes: 
clinically evident vasospasm, endovascular treatment, and 
stroke. Second, we performed a subgroup analysis to look 
at the effect of lumbar drains within each of these separate 
demographic variables. For the logistic regression models, 
the following factors were tested: the presence of a lum­
bar drain, patient’s age, intraoperative rupture of the lesion, 
EVD on admission, Fisher grade, Hunt and Hess grade, and 
source of hemorrhage. Table 3 shows the crude ORs for the 
outcomes and the adjusted ORs from the logistic regression 
models and their respective 95% CIs. The protective bene­
fit of a lumbar drain with respect to the outcomes did not 
change significantly when controlled for the factors list­
ed earlier. Covariates were considered useful in predicting 
the outcome of interest if their probability value was less 
than 0.15. The factors that were found to predict the devel­
opment of clinical vasospasm were as follows: the pres­
ence of a lumbar drain (p <  0.001), Fisher grade (p = 
0.014), anterior circulation aneurysm (p = 0.007), multiple 
aneurysms (p = 0.126), and posterior circulation aneurysms 
(p = 0.114). Use of a lumbar drain (p = 0.001), Fisher grade 
(p = 0.008), Hunt and Hess grade (p = 0.029), and anteri­
or circulation aneurysms (p = 0.009) were found to pre­
dict whether endovascular intervention was needed. Use of 
a lumbar drain (p = 0.005) and presence of anterior (p = 
0.014) and posterior (p = 0.024) circulation aneurysms were 
predictive of vasospastic stroke. Nonsignificant factors 
were patient age, intraoperative aneurysm rupture, and the 
need for EVD on admission. No factor was identified as a 
confounder or an effect modifier.
Subgroup Analysis
We performed a subgroup analysis to look at the effect of 
lumbar CSF drainage within individual Fisher grades and 
among patients who did and did not require preoperative
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TABLE 4
Subgroup analysis in patients with SAH who underwent CSF drainage
Group Risk Reduction (%)
Outcome LD Control p Value Absolute Relative
Fisher Grade 3 only
no. of patients 64
clinical vasospasm (%) 8(13)
angioplasty/papaverine (%) 8(13)
vasospasm-related infarction (%) 3 (5)
Fisher Grade 3+4 only
no. of patients 17
clinical vasospasm (%) 6 (35)
angioplasty/papaverine (%) 6 (35)
vasospasm-related infarction (%) 3 (18)
EVD on admission
no. of patients 27
clinical vasospasm (%) 5(19)
angioplasty/papaverine (%) 5(19)
vasospasm-related infarction (%) 3 (11)
no EVD on admission
no. of patients 54
clinical vasospasm (%) 9(17)
angioplasty/papaverine (%) 9(17)
vasospasm-related infarction (%) 3 (6)
EVDs (Table 4). Within Fisher Grade 3 patients only, lum­
bar CSF drainage significantly reduced the relative risk of 
clinical vasospasm, endovascular procedures, and cerebral 
infarction, by 68 , 57, and 78%, respectively. In the Fisher 
Grade 3+4 group only, the relative risk reduction of clinical 
vasospasm and the need for endovascular intervention was 
49% for both. Although the relative risk of cerebral infarc­
tion was decreased by 47%, this did not reach statistical sig­
nificance. Similar results were found in the analysis of 
patients who did and did not require an EVD on admission. 
In the former, the relative risk reduction for clinical vaso­
spasm and endovascular' procedures was 70 and 67%, re­
spectively. Again, although there was a dramatic decrease 
in the risk of cerebral infarction with a lumbar- drain (66%), 
this was not statistically significant (p = 0.05). For patients 
who did not require an EVD, the relative risk reductions for 
clinical vasospasm, need for endovascular- intervention, and 
stroke were 58, 48, and 75%, respectively. Here, the reduc­
tion in endovascular- procedures did not reach statistical sig­
nificance.
Drain Complications
Occasional complications occurred with both lumbar 
drains and EVDs, as follows. On removal of their EVDs, 
two patients suffered an intracerebral hemorrhage that re­
quired surgical evacuation. There were a number of other 
patients with small, asymptomatic hemorrhages that did not 
require treatment. In the lumbar drain group, no patient de­
veloped subdural hematomas or hygromas. In two patients 
in both the lumbar- drain and EVD groups, culture-positive 
meningitis/ventriculitis developed while the drains were in 
place. In all cases, these infections resolved after treatment 
with antibiotic drugs and removal or changing of the drain, 
with no permanent sequelae. In both groups, there were two 
patients in whom the catheters broke and surgery was re­
quired to retrieve the broken end. Thr ee patients in the lum­
bar- CSF drain group were observed to show signs of tran­
47
19 (40) 0.001 27 68
14(30) 0.024 17 57
11(23) 0.003 18 78
34
23(68) 0.028 33 49
23(68) 0.028 33 49
11 (32) 0.217 16 47
43
27(63) <0.001 44 70
25(58) 0.001 39 67
13 (30) 0.050 21 66
42
17(40) 0.009 23 58
14 (33) 0.058 16 48
10(24) 0.010 18 75
sient clinical or neurological worsening when CSF drainage 
was initiated. This consisted of a decreased level of respon­
siveness in all cases and bradycardia in two, but these signs 
cleared rapidly after clamping of the drain. We were able 
to recommence lumbar- CSF drainage successfully within 
24 to 36 hours, initially at a slow rate and then progressing 
to our target rate, without further difficulty. None of these 
three patients suffered vasospasm.
D iscussion
Impact o f Vasospasm After SAH
The impact of cerebral vasospasm on outcome after SAH 
has steadily declined over the past two decades, although it 
is still an important clinical issue. Data from the Interna­
tional Cooperative Study on the Timing of Aneurysm Sur­
gery performed in the early 1980s showed that clinical­
ly significant vasospasm permanently affected 13.5% of all 
patients and accounted for 33% of deaths and disabilities. *1 
With advances in the surveillance and management of 
vasospasm, more recent studies indicate that 5 to 11% of 
patients continue to suffer permanent disability as a result 
of vasospasm. 15'59'66'67 The current standard of care consists 
of triple-H therapy, calcium-channel antagonists, and the 
use of endovascular- reperfusion techniques. Muizelaar, et 
al.,46 have suggested the use of preemptive cerebral angio­
plasty in high-risk patients to halt the onset of vasoconstric­
tion; however, it is not yet clear- if the risk/benefit ratio of 
such an approach is justified. With the exception of preemp­
tive angioplasty, none of these current therapies prevents 
the occurrence of vasospasm, but they do lessen its clinical 
impact.
Benefits o f  Lumbar Drainage
The results of this controlled-cohort study show a 
marked benefit from lumbar CSF drainage in the following
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parameters: clinically symptomatic vasospasm, need for en­
dovascular intervention, occurrence of vasospasm-induced 
cerebral infarction, disposition at discharge, number of days 
in the ICU and total acute hospital care days, and GOS 
score measured at 1 to 3 months after discharge. The only 
outcome that did not show a statistical improvement with 
lumbar drainage was the need for a CSF shunt. Despite dif­
ferences between the lumbar drain and control groups with 
respect to Fisher grade and placement of an EVD on admis­
sion, the degree of protection provided by the lumbar drain 
was consistent throughout multivariate logistic regression 
analysis and separate subgroup analyses. The absence of a 
lumbar drain was consistently the strongest predictive fac­
tor for clinically evident vasospasm, need for endovascular 
procedures, and vasospasm-induced cerebral infarction.
Although we have performed our analysis in a subset 
of all patients with SAH presenting to the University of 
Utah Health Sciences Center, the effect of these exclusions 
was to eliminate patients at low risk for vasospasm (Fisher 
Grade 1 or 2), and those whose neurological condition after 
their hemorrhage or treatment was too poor to be impact­
ed by any subsequent vasospasm. The only other group we 
excluded from analysis was a small number of patients who 
were admitted with a delay of 4 or more days after their 
SAH. Although this group was too small to alter our results, 
we believe that this exclusion was justified on the prem­
ise that early initiation of therapy would be necessary to 
achieve protection. All other patients were included in this 
study. Even with these exclusions, demographic analysis 
showed that our patient population represented a typical 
cross-section of patients with SAH. All patients were treat­
ed by specialists in cerebrovascular surgery and with a con­
sistent postoperative vasospasm protocol, so that the only 
identifiable treatment differences were related to the use of 
lumbar CSF drains or EVDs.
Causes of and Treatments for Vasospasm
Research on the pathophysiology of cerebral vasospasm 
has related the occurrence of arterial narrowing to biochem­
ical processes that are initiated as blood undergoes lysis 
within the subarachnoid space. Factors that have been im­
plicated include oxyhemoglobin, iron, intracellular adhe­
sion molecule-1 , endothelins, nitrous oxide, reduced form 
of nicotinamide-adenine dinucleotide phosphate oxidase, 
vascular endothelial growth factor, and arachidonic acid 
derivatives.10’ 7’ 8343'^41-45-54-75-7'3 Several clinical strategies for 
reducing cerebral vasospasm have been developed based on 
these mechanisms.4-1'3-2’ 57-'38 Fibrinolytic agents, such as uro­
kinase or rt-PA, have been extensively studied.1'33'3-43-44-'3^ '35- 
70,71,74,77 -phg j-esuits from these studies indicate that there 
may be at best a slightly decreased risk of vasospasm in the 
treated groups.
A well-designed multicenter randomized trial performed 
in 1995 did not show a difference in angiographically con­
firmed or symptomatic vasospasm between patients treated 
with a single intraoperative injection of rt-PA and their con­
trol group.1'3 Nevertheless, when only patients with a thick 
subarachnoid clot were analyzed, there was a 56% relative 
risk reduction of severe vasospasm in the group treated with 
rt-PA. In contrast to this study, Kodama and colleagues353'3 
have provided evidence of a significant benefit with fibri­
nolytic therapy in an uncontrolled, nonrandomized cohort
study. They administered urokinase and ascorbic acid into 
irrigation tubes placed in the sylvian fissure (inlet) and pre- 
pontine or chiasmal cisterns (outlet) at the time of aneurysm 
clip occlusion in 222 consecutive patients with Fisher 
Grade 3 SAHs. Ascorbic acid was added because it has 
been shown to degrade oxyhemoglobin into verdoheme- 
like products, which are thought to have no prospasmo- 
genic properties.37 Clinical vasospasm occurred in only six 
patients (2.7%), two of whom suffered permanent sequelae 
(0.9%). Despite these promising results, such treatment 
has not yet become widely incorporated into current clini­
cal care.
Rationale for CSF Drainage
A number of Japanese surgeons have been using CSF 
drainage methods, including lumbar drains, since the early 
1980s, with mixed results.3233-'31 The results of our study are 
consistent with the concept of a CSF-soluble spasmogenic 
agent(s). The rationale underlying our use of lumbar CSF 
drainage is that it promotes CSF circulation from the ven­
tricles through the subarachnoid spaces, and that it also 
evacuates the large reservoir of bloody CSF from the spinal 
cistern. Conversely, CSF drainage from the ventricles may 
actually promote stasis within the subarachnoid space. It is 
our impression that patients who underwent lumbar CSF 
drainage had more rapid clearance of neuroimaging-depict­
ed blood from the subarachnoid spaces than did control 
patients, although this aspect was not specifically measured 
in this study. Moreover, of the few patients with lumbar 
CSF drainage in whom vasospasm developed, many had 
loculated pockets of hemorrhage within the subarachnoid 
cisterns or a delay in clot lysis and clearance. Based on 
these findings, we believe that it may be possible to enhance 
the overall effectiveness of lumbar CSF drainage on vaso­
spasm even further if the device was either combined with 
an irrigation catheter in the ventricles or basal cisterns, or if 
its use was combined with infusion of thrombolytic agents. 
We do not believe that the protective effect of the lumbar 
drain is gained simply through a decrease in the ICP, thus 
promoting cerebral perfusion. In both our lumbar drain and 
EVD groups, CSF diversion yielded similar values of ICP 
and for similar durations, and both TCD data and angio­
graphic results showed decreased vascular narrowing in the 
lumbar drain group. Another aspect of this therapy that 
needs further investigation is whether opening the various 
arachnoidal compartments in the basal cisterns or opening 
the lamina terminalis facilitates CSF circulation and clear­
ance of subarachnoid blood.
Complications of Lumbar Drainage
Lumbar drains are currently used in a variety of surgical 
scenarios, and are already commonly used in aneurysm 
surgery for facilitation of brain relaxation intraoperatively.7 
The published experience with lumbar drains documents 
that they can be associated with a variety of complica- 
tions.1-58-'3’ '39 Catheter breakage and infection are inherent 
risks of both EVDs and lumbar drains, and this occurred 
equally in both groups. Lumbar drains, unlike EVDs, can­
not be a direct cause of intracranial hemorrhages, but can 
cause them indirectly, especially if CSF drainage is overly 
aggressive. Tension pneumocephalus is a complication of 
lumbar CSF drainage that has been reported after transsphe­
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noidal surgery, and could be a risk related to aneurysm 
surgery if the frontal or ethmoidal sinuses are violated and 
not adequately repaired.’’ Both spinal nerve root injury and 
post-dural puncture headache are reported complications 
of spinal CSF drainage,’0 but were not encountered in our 
study. Cerebral herniation leading to death or neurologi­
cal injury is the most feared complication of lumbar CSF 
drainage, especially in postoperative patients or those with 
intracranial diseases causing mass effect. We avoided this 
complication by using a strict protocol requiring a satisfac­
tory postoperative CT scan before CSF drainage was com­
menced, and by avoiding the use of drains in patients with 
mass lesions that caused any significant cerebral midline 
shift.
We encountered several patients who transiently became 
less responsive at the start of lumbar CSF drainage with im­
mediate resolution of symptoms after clamping of the drain. 
Two of these patients had posterior fossa SAHs from pos­
terior inferior cerebellar artery aneurysms and one had a 
partially evacuated large intracerebral hematoma from an 
MCA aneurysm. In all of these individuals, we were able to 
resume lumbar CSF drainage safely within 24 hours. None 
of these patients suffered vasospasm despite having very 
substantial SAH. In all respects, safe use of postoperative 
lumbar CSF drainage in patients with aneurysms requires 
strict attention to detail, close surveillance, and an experi­
enced team of neurologically trained critical care nurses.
Limitations of the Study
There are several limitations in terms of methodology 
and outcomes in this cohort study. Selection bias is always 
a potential problem in a nonrandomized study, although 
case assignment did have a randomizing effect. Thus, pa­
tients were assigned randomly by the call schedule to 
attending physicians who either never used lumbar CSF 
drainage (control group) or to physicians who always used 
it as long as it was not contraindicated (treatment group). 
The only selection bias we could identify was a tendency to 
use lumbar drains less frequently in the group of patients 
harboring both dense cisternal subarachnoid blood and 
intracerebral hemorrhages (our Fisher Grade 3+4 group). 
As can be seen in Table 1, there were more patients in the 
control group with a Fisher Grade 3+4 hemorrhage com­
pared with the intervention (lumbar drain) group. This is 
important because this group has the highest risk of suffer­
ing vasospasm. Likewise, lumbar CSF drainage was not 
used at all in our few patients with exclusively intracerebral 
and/or intraventricular hemorrhage (Fisher Grade 4). This 
imbalance occurred because of safety concerns about the 
use of lumbar CSF drainage in patients with intracerebral 
hematomas. Lumbar drains were used in some of these pa­
tients (the ones whose hematomas had been sufficiently 
evacuated or did not cause major mass effect), and in these 
individuals the severity of cerebral vasospasm was signifi­
cantly reduced (Table 2). Nevertheless, the difference in the 
Fisher grade composition of the two groups did not prove 
to be a confounding factor based on our logistic regression 
modeling. Another limitation in our study was the fact that 
the data acquisition covered a period of 9 years; therefore, 
the data are limited by the quantity and quality of the infor­
mation obtained from the medical records.
In this study we have not presented any data as to wheth­
er lumbar CSF drainage prevents neuroimaging-conllrmed 
cerebral vasospasm. This question will be specifically ana­
lyzed in a separate study; however, our overwhelming 
impression so far is that lumbar CSF drainage actually pre­
vents arterial narrowing. The majority of patients with lum­
bar CSF drainage were noted to display only mild elevation 
of blood flow velocities on TCD studies, and surveillance 
angiography between SAH Days 7 and 9 revealed only lim­
ited vasospasm on neuroimages. Finally, in this study we 
primarily evaluated the acute management and sequelae of 
vasospasm and did not assess any long-term outcome be­
yond the 1- to 3-month GOS scores. We would expect that 
early favorable outcomes would be reflected in long-term 
favorable outcomes as well, but this will need to be con­
firmed in future studies.
C onclusions
This controlled, nonrandomized cohort study represents 
our extensive experience with lumbar CSF drainage over 
the last 9 years. With this technique, we have shown a 
marked reduction in the risk of suffering clinically symp­
tomatic vasospasm, vasospasm-induced stroke, and in the 
need for endovascular procedures for neurological rescue. 
Number of days in the ICU and overall hospital stay were 
reduced, as was the need for rehabilitation or convalescent 
care. The risk of chronic hydrocephalus, however, was not 
significantly changed with use of a lumbar drain, although 
there was a favorable trend. Lumbar drains are believed to 
decrease cerebral vasospasm by promoting circulation of 
CSF and clearance of blood from the subarachnoid spaces. 
The complication rate with lumbar drains was no greater 
than that associated with EVDs, but appropriate precautions 
must be observed when using the former. On the basis of 
our study, a randomized prospective trial of this therapy 
is warranted and is currently under way. The present report 
was primarily a surgical aneurysm series, and this approach 
should also be investigated to see if it would decrease cere­
bral vasospasm in endovascularly treated patients as well.
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